128 related articles for article (PubMed ID: 23264224)
21. Diagnostic Power of Cytokine M-CSF, Metalloproteinase 2 (MMP-2) and Tissue Inhibitor-2 (TIMP-2) in Cervical Cancer Patients Based on ROC Analysis.
Lubowicka E; Zbucka-Kretowska M; Sidorkiewicz I; Zajkowska M; Gacuta E; Puchnarewicz A; Chrostek L; Szmitkowski M; Ławicki S
Pathol Oncol Res; 2020 Apr; 26(2):791-800. PubMed ID: 30820752
[TBL] [Abstract][Full Text] [Related]
22. [Significance of CEA, SCC and Cyfra21-1 serum test in esophageal cancer].
Mao YS; Zhang DC; Zhao XH; Wang LJ; Qi J; Li XX
Zhonghua Zhong Liu Za Zhi; 2003 Sep; 25(5):457-60. PubMed ID: 14575569
[TBL] [Abstract][Full Text] [Related]
23. Serum tissue inhibitor of metalloproteinase-2 (TIMP-2) and matrix metalloproteinase-2 in complex with the inhibitor (MMP-2:TIMP-2) as prognostic markers in bladder cancer.
Vasala K; Turpeenniemi-Hujanen T
Clin Biochem; 2007 Jun; 40(9-10):640-4. PubMed ID: 17374529
[TBL] [Abstract][Full Text] [Related]
24. [Value of the concentration and integrity of serum cell-free DNA for the clinical diagnosis of esophageal carcinoma].
Qiu YW; Shen XJ; Jin CJ; Cao XJ; Ju SQ
Zhonghua Zhong Liu Za Zhi; 2018 Dec; 40(12):905-910. PubMed ID: 30605980
[No Abstract] [Full Text] [Related]
25. Clinical significance of serum carcinoembryonic antigen, carbohydrate antigen 19-9, and squamous cell carcinoma antigen levels in esophageal cancer patients.
Kosugi S; Nishimaki T; Kanda T; Nakagawa S; Ohashi M; Hatakeyama K
World J Surg; 2004 Jul; 28(7):680-5. PubMed ID: 15383868
[TBL] [Abstract][Full Text] [Related]
26. [Assay of matrix metalloproteinase levels and their endogenous inhibitors in patients with laryngeal carcinoma].
Klisho EV; Savenkova OV; Kondakova IV; Perel'muter VM; Choĭnzonov EL; Shishkin DA
Vopr Onkol; 2007; 53(1):26-31. PubMed ID: 17649730
[TBL] [Abstract][Full Text] [Related]
27. Human Plasma Levels of Vascular Endothelial Growth Factor, Matrix Metalloproteinase 9, and Tissue Inhibitor of Matrix Metalloproteinase 1 and Their Applicability as Tumor Markers in Diagnoses of Cervical Cancer Based on ROC Analysis.
Zajkowska M; Zbucka-Krętowska M; Sidorkiewicz I; Lubowicka E; Będkowska GE; Gacuta E; Szmitkowski M; Ławicki S
Cancer Control; 2018; 25(1):1073274818789357. PubMed ID: 30037277
[TBL] [Abstract][Full Text] [Related]
28. The diagnostic value of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) determination in the sera of colorectal adenoma and cancer patients.
Mroczko B; Groblewska M; Okulczyk B; Kedra B; Szmitkowski M
Int J Colorectal Dis; 2010 Oct; 25(10):1177-84. PubMed ID: 20556397
[TBL] [Abstract][Full Text] [Related]
29. Clinical Significance of Matrix Metalloproteinases in Blood Plasma of Patients with Gastric Cancer.
Kushlinskii NE; Gershtein ES; Ivannikov AA; Davydov MM; Chang VL; Ognerubov NA; Stilidi IS
Bull Exp Biol Med; 2019 Jan; 166(3):373-376. PubMed ID: 30627896
[TBL] [Abstract][Full Text] [Related]
30. [Expression and significance of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase in non-melanoma skin cancer].
Fu XR; Zhang C; Chen CY; Zhang L; Wang LX; Wang BH; Liu XY; Zhang MZ
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):369-73. PubMed ID: 22883459
[TBL] [Abstract][Full Text] [Related]
31. The role of matrix metalloproteinase MMP-9 and TIMP-2 tissue inhibitor of metalloproteinases as serum markers of bladder cancer.
Ramón de Fata F; Ferruelo A; Andrés G; Gimbernat H; Sánchez-Chapado M; Angulo JC
Actas Urol Esp; 2013 Sep; 37(8):480-8. PubMed ID: 23916137
[TBL] [Abstract][Full Text] [Related]
32. Prediction of survival with squamous cell carcinoma antigen in patients with resectable esophageal squamous cell carcinoma.
Shimada H; Nabeya Y; Okazumi S; Matsubara H; Shiratori T; Gunji Y; Kobayashi S; Hayashi H; Ochiai T
Surgery; 2003 May; 133(5):486-94. PubMed ID: 12773976
[TBL] [Abstract][Full Text] [Related]
33. Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor.
Rauvala M; Puistola U; Turpeenniemi-Hujanen T
Gynecol Oncol; 2005 Dec; 99(3):656-63. PubMed ID: 16112717
[TBL] [Abstract][Full Text] [Related]
34. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
[TBL] [Abstract][Full Text] [Related]
35. The prognostic factors after radical esophagectomy for esophageal cancer with positive preoperative CEA.
Takemura M; Osugi H; Takada N; Okuda E; Ueno M; Kinoshita H
Hepatogastroenterology; 2004; 51(55):159-62. PubMed ID: 15011854
[TBL] [Abstract][Full Text] [Related]
36. Serum levels and tissue expression of matrix metalloproteinase 2 (MMP-2) and tissue inhibitor of metalloproteinases 2 (TIMP-2) in colorectal cancer patients.
Groblewska M; Mroczko B; Gryko M; Pryczynicz A; Guzińska-Ustymowicz K; Kędra B; Kemona A; Szmitkowski M
Tumour Biol; 2014 Apr; 35(4):3793-802. PubMed ID: 24395652
[TBL] [Abstract][Full Text] [Related]
37. Serum tissue inhibitor of metalloproteinase 1 (TIMP-1) and vascular endothelial growth factor A (VEGF-A) are associated with prognosis in esophageal cancer patients.
Kozłowski M; Laudański W; Mroczko B; Szmitkowski M; Milewski R; Łapuć G
Adv Med Sci; 2013; 58(2):227-34. PubMed ID: 23773968
[TBL] [Abstract][Full Text] [Related]
38. The prognostic role of tissue and serum MMP-1 and TIMP-1 expression in patients with non-small cell lung cancer.
An HJ; Lee YJ; Hong SA; Kim JO; Lee KY; Kim YK; Park JK; Kang JH
Pathol Res Pract; 2016 May; 212(5):357-64. PubMed ID: 26995105
[TBL] [Abstract][Full Text] [Related]
39. Circulating gelatinases and tissue inhibitor of metalloproteinase-1 in colorectal cancer metastatic liver disease.
Waas ET; Wobbes T; Ruers T; Lomme RM; Hendriks T
Eur J Surg Oncol; 2006 Sep; 32(7):756-63. PubMed ID: 16650961
[TBL] [Abstract][Full Text] [Related]
40. Clinical significance of osteopontin in esophageal squamous cell carcinoma: comparison with common tumor markers.
Shimada Y; Watanabe G; Kawamura J; Soma T; Okabe M; Ito T; Inoue H; Kondo M; Mori Y; Tanaka E; Imamura M
Oncology; 2005; 68(2-3):285-92. PubMed ID: 16015046
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
